Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by...
-
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat...
-
Annovis will host corporate update webinar on January 28, 2026
-
RetinalGenix signs agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026
-
Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.
-
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
-
MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for...
-
Gnome Sciences Discovers Cancer Drug Shows Promise in Stopping Progression of ALS. BCL2 inhibitors such as venetoclax may treat neurodegenerative diseases
-
SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- A comprehensive systematic review of lifestyle interventions to prevent cognitive decline, which published in the prestigious British medical journal...
-
All 84 sites for pivotal Phase 3 study in early AD are now fully activated, and the first group of patients has completed the 6-month treatment period.